1394033-54-5 Usage
General Description
PF-05180999, also known as rucaparib, is a chemical compound that belongs to the class of poly(ADP-ribose) polymerase (PARP) inhibitors. It works by inhibiting the enzyme PARP, which plays a role in repairing damaged DNA. By doing so, PF-05180999 prevents cancer cells from repairing their DNA, ultimately leading to cell death. This makes it a promising candidate for the treatment of various cancers, particularly those associated with mutations in BRCA genes. Clinical trials have shown its effectiveness in treating ovarian, breast, and prostate cancers in patients with specific genetic mutations. It is currently approved for the treatment of certain types of ovarian and prostate cancers and is being investigated for its potential in other cancer types as well.
Check Digit Verification of cas no
The CAS Registry Mumber 1394033-54-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,4,0,3 and 3 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1394033-54:
(9*1)+(8*3)+(7*9)+(6*4)+(5*0)+(4*3)+(3*3)+(2*5)+(1*4)=155
155 % 10 = 5
So 1394033-54-5 is a valid CAS Registry Number.
1394033-54-5Relevant articles and documents
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate
Helal, Christopher J.,Arnold, Eric,Boyden, Tracey,Chang, Cheng,Chappie, Thomas A.,Fisher, Ethan,Hajos, Mihaly,Harms, John F.,Hoffman, William E.,Humphrey, John M.,Pandit, Jayvardhan,Kang, Zhijun,Kleiman, Robin J.,Kormos, Bethany L.,Lee, Che-Wah,Lu, Jiemin,Maklad, Noha,McDowell, Laura,McGinnis, Dina,O'Connor, Rebecca E.,O'Donnell, Christopher J.,Ogden, Adam,Piotrowski, Mary,Schmidt, Christopher J.,Seymour, Patricia A.,Ueno, Hirokazu,Vansell, Nichole,Verhoest, Patrick R.,Yang, Edward X.
, p. 1001 - 1018 (2018/02/17)
Computational modeling was used to direct the synthesis of analogs of previously reported phosphodiesterase 2A (PDE2A) inhibitor 1 with an imidazotriazine core to yield compounds of significantly enhanced potency. The analog PF-05180999 (30) was subsequen
